Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 16-Aug-22 4:25 PM View:  | Werner Milton H. President and CEO Director 10% Owner | Inhibikase Therapeutics, Inc. (IKT) | 16-Aug-22 | Private Purchase | 5,000 | $0.80 | $4,000.00 | < 1% 5.33M to 5.34M | |
| 31-May-22 10:16 AM View: | Werner Milton H. President and CEO Director 10% Owner | Inhibikase Therapeutics, Inc. (IKT) | 27-May-22 | Private Purchase | 5,000 | $0.98 | $4,880.00 | < 1% 5.33M to 5.33M | |
| 23-May-22 4:57 PM View: | Werner Milton H. President and CEO Director 10% Owner | Inhibikase Therapeutics, Inc. (IKT) | 20-May-22 | Private Purchase | 10,000 | $0.60 | $6,000.00 | < 1% 5.32M to 5.33M | |
| 23-May-22 4:54 PM View: | Frattaroli Joseph Chief Financial Officer | Inhibikase Therapeutics, Inc. (IKT) | 19-May-22 | Private Purchase | 3,948 | $0.64 | $2,542.51 | 9% 44.14K to 48.09K | |
| 04-Jan-22 9:25 PM View: | Werner Milton H. President and CEO Director 10% Owner | Inhibikase Therapeutics, Inc. (IKT) | 03-Jan-22 | Option Exercise | 21,853 | $2.02 | $44,143.10 | < 1% 5.29M to 5.32M | |
| 19-Nov-21 8:13 AM View: | Werner Milton H. President and CEO Director 10% Owner | Inhibikase Therapeutics, Inc. (IKT) | 17-Nov-21 | Market Purchase | 23,589 | $1.97 | $46,558.10 | < 1% 5.29M to 5.32M | (4%) |
| 19-Aug-21 7:46 AM View: | Werner Milton H. President and CEO Director 10% Owner | Inhibikase Therapeutics, Inc. (IKT) | 17-Aug-21 | Option Exercise | 21,853 | $2.02 | $44,143.10 | < 1% 5.27M to 5.29M | (3%) |
| 18-May-21 5:46 PM View: | Werner Milton H. President and CEO Director 10% Owner | Inhibikase Therapeutics, Inc. (IKT) | 14-May-21 | Payment of Exercise | 16,918 | $4.59 | $77,653.60 | (< 1%) 5.29M to 5.27M | |
| 18-May-21 5:46 PM View: | Werner Milton H. President and CEO Director 10% Owner | Inhibikase Therapeutics, Inc. (IKT) | 14-May-21 | Option Exercise | 43,707 | $0.38 | $16,608.70 | < 1% 5.24M to 5.29M | |
| 29-Dec-20 9:52 PM View: | Frattaroli Joseph Chief Financial Officer | Inhibikase Therapeutics, Inc. (IKT) | 28-Dec-20 | Conversion | 44,143 | $10.00 | $441,430.00 | 100% 0 to 44.14K |
